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 ECCO Essential Requirements for Quality Cancer Care (ERQCC) are position papers on 
delivering high-quality care  
 Each paper focuses on a cancer type, in this case prostate cancer 
 Prostate cancer is a major healthcare burden and has complex treatment options 
 High-quality care can only be a carried out in specialised units or centres  
 The essential, multidisciplinary details for such centres are set out by the ERQCC 







ECCO Essential Requirements for Quality Cancer Care (ERQCC) are written by experts 
representing all disciplines involved in cancer care in Europe. They give oncology teams, 




 Prostate cancer is the second most common male cancer and has a wide variation in 
outcomes in Europe. It has complex diagnosis and treatment challenges, and is a 
major healthcare burden.  
 Care must only be a carried out in prostate/urology cancer units or centres that have 
a core multidisciplinary team (MDT) and an extended team of health professionals. 
Such units are far from universal in European countries.  
 To meet European aspirations for comprehensive cancer control, healthcare 
organisations must consider the requirements in this paper, paying particular 
attention to multidisciplinarity and patient-centred pathways from diagnosis, to 
treatment, to survivorship.        















1 Introduction: the need for quality frameworks  
 
There has been a growing emphasis on driving up quality in cancer organisations given 
variations in outcomes in Europe. The European Cancer Concord (ECC), a partnership of 
patients, advocates and cancer professionals, recognised major disparities in the quality of 
cancer management and in the degree of funding in Europe in its European Cancer Patient’s 
Bill of Rights, a patient charter that underpins equitable access to optimal cancer control, 
cancer care and research for Europe’s citizens. [1] 
This followed an assessment of the quality of cancer care in Europe as part of the first EU 
Joint Action on Cancer, the European Partnership for Action Against Cancer (EPAAC, 
http://www.epaac.eu), which reported that there are important variations in service delivery 
between and within countries, with repercussions in quality of care. Factors such as waiting 
times and provision of optimal treatment can explain about a third of the differences in cancer 
survival among countries, while lack of a national cancer plan that promotes clinical 
guidelines, professional training and quality control measures, may be responsible for a 
quarter of the survival differences.  
The EU Joint Action on Cancer Control (CANCON), which succeeded EPAAC from 2014, 
also focused on quality of cancer care and published in 2017 the European Guide on Quality 
Improvement in Comprehensive Cancer Control. [2] This report recognised that many cancer 
patients are treated in general hospitals and not in comprehensive cancer centres (CCCs), 
and explored a model of ‘comprehensive cancer care networks’ that can integrate expertise 
under a single governance structure. Further, research shows that care provided by 
multidisciplinary teams (MDTs) results in better clinical and organisational outcomes for 
patients [3] and that they are the core component in cancer care. [4] 
Countries have been concentrating expertise for certain tumour types in such networks and in 
dedicated centres, or units, such as those for childhood and rare cancers, and all CCCs have 
teams for the main cancer types. For common adult tumours, however, at the European level 
there has been widespread effort to establish universal, dedicated units only for breast 
cancer, following several European declarations that set a target at the year 2016 for care of 
all patients with breast cancer to be delivered in specialist multidisciplinary centres. While this 
target was not met, [5] the view of the ERQCC expert group is that patients with all tumour 
types should have this dedicated care.  
 
 
1.1 Prostate cancer 
Prostate cancer is perhaps the closest behind breast cancer in terms of establishing a 
European concept of a tumour-specific cancer unit. Following the publication of a discussion 
paper by the European School of Oncology (ESO) in 2011 on the requirements of a specialist 
prostate cancer unit, [6] the Prostate Cancer Unit (PCU) initiative was launched. A position 
paper in 2015 then set out the first mandatory and recommended standards including 
requirements for organising and treating prostate cancer in units. [7] The European 
Association of Urology has also recently put forward a ‘centres of excellence’ proposal for 
prostate cancer centres. [8] This ERQCC paper sets out essential requirements for the 
organisation of prostate cancer units in Europe in the context of challenges and resources in 
















2 Prostate cancer: key facts and challenges  
 
2.1 Key facts  
 
2.1.1 Epidemiology 
 Prostate cancer is a disease of the prostate gland, which is located just below the bladder 
and surrounds the urethra. It is the second most common cancer in men globally, after 
lung cancer. The main type of prostate cancer is acinar adenocarcinoma, which develops 
in the glandular cells of the prostate, and which accounts for about 99% of cases. Much 
less common types are ductal adenocarcinoma, urothelial, squamous cell, 
neuroendocrine (carcinoid) tumours and sarcomas. Prostate cancer is the most common 
male cancer in Europe and is a substantial disease burden likely to increase due to an 
ageing population.  
 The estimated European incidence of prostate cancer in 2018 was about 460,000. [9] 
Mortality was about 107,000. The estimated incidence was highest in Ireland, Estonia and 
Norway (Ireland highest at 265/100,000 age standardised rate), and lowest in Romania 
and Poland (Romania lowest at 80). Mortality was highest in Estonia (73.9/100,000 ASR), 





Figure 1: European regional prostate cancer mortality and incidence. Source: European Cancer 
Information System (ECIS) 
 
 
 There are high survival rates for prostate cancer in Europe with increases in recent years. 
The EUROCARE-5 study (the most recent pan-European survival study) reports 1 year/5 
year relative survival in Europe for prostate cancer patients diagnosed between 2000–
2007 at 95% and 83%, respectively, and notes that the 5-year rate increased from 73% in 
2005–2007 to 82% in 2005–2007. [10] More recent data from England and Wales shows 
a 84.8% 5 year survival rate for men diagnosed in 2010/11. [11] Increases in incidence 
and survival must be interpreted with caution given the varying prevalence of prostate 
specific antigen (PSA) testing and consequent biopsy rates, which uncovers a proportion 
of patients harbouring a disease that would have remained dormant and likely not been 
subject to further progression. The EUROCARE-5 authors note that incidence varied by 
more than 7-fold in Europe, and also that in addition to PSA testing, the variability of 
diagnostic techniques and higher socioeconomic status are factors in increased 
incidence. In contrast, mortality rates are a better indication of risk, although there are 
several challenges in the attribution of causes of death in older men. However, incidence 
of prostate cancer has been rising in Asia (Japan, Singapore and Thailand) where PSA 
testing has been less common, which may suggest a possible role of ‘westernisation’ of 
lifestyles, leading to globally increasing prostate cancer incidence rates in most countries. 
[12] 
 
2.1.2 Risk factors 
 The main risk factor for prostate cancer is older age (only 25% of cases in Europe are 
in men diagnosed before age 65). [13] Furthermore, men of African-Caribbean and 














cancers can be attributed to hereditary factors. Family history and mutations, 
especially in the BRCA1 and BRCA2 genes, increase the risk, and decreases the age 
at which prostate cancer is detected. There are no clear preventable risk factors; 
there is limited or probable evidence for factors including anabolic steroids, red meat 
and obesity, and some industrial and toxic substance exposure. Probable risk factors 
also include physical inactivity, a diet high in calcium and phosphorus, and smoking, 
which may be risk factors for more aggressive disease.  
 
2.1.3 Diagnosis  
 Most men with early prostate cancer do not have clinical symptoms. Symptoms such 
as more frequent urination and urgency to urinate are mostly caused by benign 
prostatic hyperplasia, which is a common enlargement of the prostate in older men. 
Other symptoms that may lead to diagnosis are visible haematuria (blood in the urine) 
and haematospermia (blood in semen) when the tumour affects the seminal vesicles 
or all of the prostate gland. Metastatic prostate cancer can cause a variety of 
symptoms according to the localisation of metastasis, most usually bone pain. 
 Initial investigations for suspected prostate cancer are often a PSA test followed by a 
digital rectal examination to feel for abnormalities on the gland. A common procedure 
for diagnosing primary prostate cancer is a transrectal ultrasound (TRUS) guided 
biopsy followed by staging and grading by pathologists according to the TNM and 
Gleason systems. [14,15] This can be targeted by ultrasound to the area of the 
prostate identified by multiparametric magnetic resonance imaging (mpMRI) scans, 
defined as cognitive, in-bore or fusion biopsy, which are the preferred investigations. 
[16] Transperineal biopsies are preferred to enable correct sampling of the anterior 
prostate gland. A number of methods are under investigation to reduce the number of 
unnecessary biopsies, including upfront mpMRI, [17] analysis of PSA density and 
kinetics, risk calculators such as the 4Kscore, the Prostate Health Index, and testing 
for prostate cancer gene 3, PCA3.  
 Imaging – mpMRI, CT, ultrasound and bone scan – is used for local staging and to 
determine spread outside the prostate. MpMRI provides a detailed scan of the 
prostate and can also be taken before a biopsy to see if a biopsy is needed and if so 
to optimise its location within the prostate.  
 New sonographic modalities such as contrast-enhanced ultrasound and sono-
elastography are under investigation to detect and stage prostate cancer. [18,19] 
Gallium and fluoride PSMA PET/CT scans are being evaluated in upfront imaging in 





 There is a wide variety of clinical options in prostate cancer, according to risk factors 
related to the disease (clinical stage, PSA, Gleason score, International Society of 
Urological Pathology Grade Groups) and the patient’s life expectancy. [14] 
 Less aggressive disease can be monitored without any active treatment according to 
active surveillance protocols.  
 Possible radical treatments are surgery (open, laparoscopic or robot-assisted), 
external beam radiation therapy (EBRT) and brachytherapy (BRT). Alternative 
surgical techniques (focal therapy) or radiation techniques such as stereotactic body 
radiation therapy (SBRT) are under evaluation.  
 More aggressive or locally advanced disease is treated with a multimodal approach 
(i.e. surgery followed by EBRT and/or androgen deprivation therapy (ADT); EBRT 
plus BRT and ADT, EBRT plus ADT). 
 ADT, chemotherapy, other hormonal treatments (abiraterone and enzalutamide) and 
radium-223 are treatment options for patients with metastatic and/or castrate resistant 
prostate cancer. [20] Treatment with curative intent of oligometastasis (typically up to 
3, recently extending to 5, metastases) is the subject of research. [21,22] 
 Treatment options can be summarised in risk categories as:  
– Very low: active surveillance 
– Low: active surveillance, focal therapy, radiation therapy or prostatectomy 
– Intermediate: radical prostatectomy or radiation therapy 
– High: radical prostatectomy plus post-operative radiation therapy or radical 


















2.2 Challenges in prostate cancer care  
 
2.2.1 Screening and detection  
 The use of the PSA test to detect prostate cancer is one of the most controversial topics 
in current medical practice, with contrasting views in the US and Europe. Two major 
randomised controlled trials (RCTs) on screening came to opposite conclusions on its 
merits, [23,24] and while a statistical analysis of both has reported a 16% reduction in 
prostate cancer mortality of those screened [25] there has been no move by health 
policymakers to introduce population-based screening owing to the PSA test’s lack of 
sensitivity for detecting harmful cancer together with large potential for unnecessary harm 
in painful biopsies and life-changing interventions for slow-growing tumours that needed 
no treatment. Indeed, other recent research, for example from the UK, has shown no 
difference in mortality from men having a one-time PSA test than those who did not. [26] 
PSA presents a major dilemma for healthy men and their primary care doctors and 
urologists as to whether to take a test. Many doctors continue to recommend PSA tests, 
and a secondary effect of testing is overdiagnosis and overtreatment that skews 
comparisons in incidence and survival among countries. Guidelines on the PSA test must 
be used to help inform the patient (as in the EAU-ESTRO-SIOG guidelines). [14]  
 Generating awareness of prostate health and symptoms of prostate cancer among men 
and their partners or carers remains a major challenge given that men tend to ignore or 
defer health-related changes of all types. Diagnosis of prostate cancer is typically made at 
a more advanced stage than breast cancer, although 40-50% of new diagnoses are in low 
and very low risk cases. The Movember campaign (https://www.movember.com) and 
testimonies of male celebrities diagnosed with prostate cancer have helped, and the role 
of advocacy organisations such as Europa Uomo – which unites national prostate cancer 
support groups – is crucial, although there is still a way to go before matching the 
progress made in breast cancer.  
 There is evidence that despite primary care doctors being alerted to refer people to see 
specialists for all cancers within certain times, men with suspected prostate cancer wait 
longer than those suspected of other cancers. [27] Apart from the possibility of missing 
treatment time for aggressive disease, this can also exacerbate psychological distress.  
 
2.2.2 Diagnosis  
 
Diagnosing, staging and grading prostate cancer is complex and it is essential that 
experienced pathologists and radiologists and nuclear medicine specialists determine results 
from biopsies, surgery samples and imaging. Challenges include:  
 The need to be able to detect aggressive, potentially lethal prostate cancers, that 
must receive treatment (or combined and sequenced treatments) vs. indolent, 
insignificant cancers that do not cause death and could be followed up in active 
surveillance programmes 
 The need to develop non-invasive tools to diagnose exclusively clinically significant 
prostate cancer.  
A multidisciplinary approach can be especially important in these early steps; a clinic that 
evaluated men with newly diagnosed prostate cancer in a timespan of only 1 day, with a 
meeting where imaging studies and biopsy slides were reviewed with collaboration of 
urologists, radiation oncologists, medical oncologists, pathologists and radiologists, showed 
that many men were then given a different risk category or stage as a result. [28] 
 
 
2.2.3 Treatment  
 
 Radical prostatectomy is a procedure that has a wide variation in surgeon volumes 
and complication outcomes. [29] The specialism of urology, which traditionally cares 
for urological cancers, requires surgeons who are cancer specialists and who work in 
prostate units as advocated in this paper, and who have completed sufficient 














 Radiation therapy can now be delivered by a wide variety of techniques, increasing 
complexity and treatment choice. 
 In addition to treatment complexity, choosing between treatments that have 
equivalent survival outcomes is a major challenge for patients, as is securing access 
to appropriate information that will inform their preferred approach. It is important that 
men have access to balanced and unambiguous information from all appropriate 
members of the MDT, especially where there are competing choices of treatment. For 
example, studies have showed:  
– Men who consult a radiation oncologist as well as a urologist are more likely to 
opt for radiation therapy to treat localised cancer [30,31] 
– A multidisciplinary consultation in the initial management of non-metastatic 
prostate cancer has been found to give high patient satisfaction, promote active 
participation and shared decision-making and strongly influenced the final patient 
decision [32] 
– A high level of patient satisfaction was reported at a longstanding multidisciplinary 
clinic, which also reported a survival benefit for advanced disease [33] 
– Multidisciplinary care has been found to be associated with increased selection of 
active surveillance in men with low-risk prostate cancer. [34] 
 Recent medical therapies are bringing more complexity and costs for non-surgical 
oncology. 
 Decision aids for treatment and diagnosis are a growing area of interest and require 
support for implementation. [35,36] 
 
2.2.4 Support services and survivorship 
 A diagnosis of prostate cancer can have a devastating effect on the mental health 
and wellbeing of men [37] and a range of unmet physical, psychological and 
information needs have been identified. [38]  
 As more men are living with the after-effects of prostate cancer treatments, and with 
advanced disease, there has been an increasing demand for high-quality support 
services. Up to 75% of men treated for localised prostate cancer report severe and 
persistent treatment side‐effects including sexual dysfunction, and poor urinary or 
bowel function. [39] Treatment complications may be life-long and have intense 
psychological impact on masculinity.  
 It is a challenge to make support available for not only the range of physical effects of 
treatment, from incontinence and erectile dysfunction to symptoms of advanced 
cancer, to effects of hormone therapy, but also psychological and counselling support 
for issues such as sexuality. It is essential that an extended community of nurses, 
physiotherapists, psychologists, sexual therapists, social workers and palliative care 
specialists is in place.  
  
 
2.2.5 Genetic testing and counselling 
Prostate cancer has a substantial heritable component that has been said to be under-
appreciated in the urologic community. [40,41] It is likely that in future genetic testing and 
counselling will become important in standards of care, placing pressure on healthcare 
systems to provide more clinical geneticists and support teams. [42,43]  
 
2.2.6 Inequalities  
 The variation in outcomes for prostate cancer in Europe indicates that there may be 
inequalities in access to high-quality care, although comparisons are hard to make 
owing to widely varying incidence and quality of registry information. What is certain is 
that as with other cancers, some countries in eastern Europe lack access to drugs, 
radiation therapy and new techniques that may be critical to improving care.  
 As prostate cancer is primarily a disease of older men, there are pronounced 
challenges in caring for a population that has more co-morbidities and in making 
shared and informed treatment decisions. Research from the Netherlands [44] and 
Italy [45] has also showed that the probability of receiving treatment with curative 













across age groups for intermediate- and high-risk patients who underwent treatment 
with curative intent. Not age, but patient preferences, together with life expectancy, 
and comorbidity should be decisive factors when offering treatment. 
 While there is evidence that men from higher socioeconomic groups have a higher 
incidence of prostate cancer, which may be due to increased take up of screening, 
they are also more likely to receive curative and non-curative treatment than lower 
socioeconomic groups. [46,47] 
 The increased incidence in men of African and African-Caribbean ethnicity is a 
challenge in reaching groups that are often socioeconomically disadvantaged.  
 
2.2.7 Research 
The range of research challenges for prostate cancer is wide, extending from risk stratification 
at diagnosis, to new localised treatment techniques, to individualising medical treatments as 
new agents become available for advanced disease, to improving quality of life. Funding for 
prostate cancer research lags behind other cancers in many countries and participation in 
research and/or research networks is needed.   
 
 
3 Organisation of care  
 
 
3.1 Care pathways and timelines 
 
 Care for men with prostate cancer patients must be organised in pathways that cover the 
patient’s journey from their point of view rather than that of the healthcare system, and 
pathways must correspond to current national and European evidence-based clinical 
practice guidelines on diagnosis, treatment and follow-up. The European Pathway 
Association defines a care pathway as “a complex intervention for the mutual decision 
making and organisation of care processes for a well-defined group of patients during a 
well-defined period”. This broad definition covers terms such as clinical, critical, integrated 
and patient pathways that are also often used. See http://e-p-a.org/care-pathways and 
also the WHO framework on integrated people-centred health services, 
http://www.who.int/servicedeliverysafety/areas/people-centred-care. 
 After a diagnosis, it must be clear to the patient which professional is responsible for each 
step in the treatment pathway and who is following the patient during the journey (usually 
called a case manager or patient navigator). [48] In some countries, case managers 
during the main stages of treatment are cancer nurses. 
 Follow-up, support and care for long-term survivorship, and palliative care, must be part 
of a care pathway.  
 
3.2 Prostate cancer units/centres 
 
 The concept of the multidisciplinary prostate cancer unit, as initially set out by the 
European School of Oncology (ESO), is recent in Europe (and elsewhere). [6] In that 
paper, the prostate cancer unit was not put forward necessarily as a single location but 
departments needed to be in ‘reasonable proximity to provide a stable structure for teams 
of specialists to work together’, which was confirmed in the follow-up paper published in 
2015. [7] The ERQCC expert group considers that it is optimal for a unit to be based at a 
single site for most of the core and extended specialties, in line with the essential 
requirements for other cancers (and in particular as pioneered in breast cancer). 
However, it is recognised that some members of the MDT may be based at nearby 
locations, and that some patients will not live near specialist units, in which case there 
must be a structure in place to enable discussion of patient management in weekly 
teleconferences with an expert centre. 
 Prostate cancer clinics are likely to be co-located with other urological cancers (bladder, 
kidney, testicular), but each cancer must have its own MDT and minimum volume, 
performance and audit requirements. It is likely that prostate cancer units will be 
established in large hospitals or in cancer centres that cater for a population of more than 
300,000 people, and have a MDT and resources that can care for 100 or more newly 














been to transfer urological services to fewer centres to meet guidance of a minimum of 50 
radical prostatectomies and radical cystectomies (for bladder cancer) per year [49] (NICE 
recommends that robotic surgery should have a minimum of 150 cases a year). [15] The 
target for certification of a prostate cancer centre in Germany is at least 50 radical 
prostatectomies/cystoprostatectomies a year (and the last audit reported a median 
number of 79). [50]  
 The evidence for a minimum volume of prostatectomies carried out by individual surgeons 
has been the most extensively studied in prostate cancer treatment: 
– A study on case volume reports that the hospital length of stay, rates of perioperative 
complications, transfusions, incontinence, and erectile dysfunction are higher among 
patients treated by lower volume surgeons [51]  
– A systematic review on the volume-outcome relationship for radical prostatectomy 
looked at studies by hospital and/or surgeon volume, finding conflicting evidence on 
their relative contribution to better outcomes. [52] The authors also noted that in the 
US, 80% of surgeons performed ≤10 radical prostatectomies; only 5% performed ≥50 
cases  
– Another systematic review also found that higher surgical volume was associated with 
improved outcomes for radical prostatectomy. [53] 
 The ERQCC expert group considers that a volume target of 100 cases (all stages of 
prostate cancer) and a minimum of 50 prostatectomies a year conducted by two or more 
urologists is an essential requirement for a prostate cancer unit. This does not include a 
target for an individual surgeon, but the requirement is also for a urologist to spend at 
least 50% of their time on prostate cancer. While the 100/50 target and more has been 
specified in countries such as Germany and the UK, there are currently lower 
specifications, such as in the Netherlands, which while listing the same core MDT as this 
ERQCC paper in a standardisation document, specifies a minimum volume of only 20 
radical prostatectomies per year for a hospital. [54] The 2015 position paper from ESO 
[7] also agreed the 100/50 target.  
 
 
3.3 The MDT for prostate cancer  
 
Treatment strategies for all prostate cancer patients must be decided on, planned and 
delivered as a result of consensus among a core MDT that comprises the most appropriate 
members for the particular diagnosis and stage of cancer, patient characteristics and 
preferences, and with input from the extended community of professionals. The heart of this 
decision-making process is normally a weekly or more frequent MDT meeting where all cases 
are discussed with the objective of balancing the recommendations of clinical guidelines with 
the needs of the individual prostate cancer patient. 
To properly treat prostate cancer, it is essential that the core MDT comprises health 




 Nuclear medicine 
 Urology/surgery  
 Radiation oncology 
 Medical oncology 
 Nursing. 
 
A director who coordinates the work of all these specialists is essential to facilitate meetings 
and discussions. A multidisciplinary group can be led by urologists, medical oncologists or 
radiation oncologists. 
 
According to the case, some or all of this core MDT meets to discuss: 
 Cases after diagnosis and staging to decide on optimal treatment according to 
categorisation in low-, intermediate- and high-risk categories 
 Patients with a recurrence, or where changes to treatment programmes are indicated 
















Healthcare professionals from the following disciplines must also be available whenever their 
expertise is required (the ‘extended’ MDT):  
 
 Oncology pharmacy 
 Geriatric oncology 
 Psycho-oncology 
 Physiotherapy 
 Palliative care 
























3.4 Disciplines in the core MDT 
 
General statement: Core MDT members, in particular urologists, radiation oncologists, 
medical/clinical oncologists and nurses, must have excellent communications skills to engage 
patients and their family and carers in the benefits and risks of therapies to ensure that 
treatment options are explained to and are appropriate for the patient, and are not unduly 




3.4.1 Pathology  
Pathologists play a vital role in the MDT in timely diagnosis, staging, prognostic/predictive 
assessment and clinical decision making for each patient. In prostate cancer the pathologist 
conducts detailed studies of samples taken from biopsies and resections (surgical samples).  
 
Essential requirements 
 There must be at least one uro-pathologist responsible for prostate cancer who must 
spend at least 50% of their time on uro-pathology. 
 Pathologists must have expertise in reporting on preoperative prostate biopsies and 
prostatectomies and must use structured reports that meet internationally 
standardised and evidence-based datasets for the reporting of cancer pathology. [55] 
 Pathologists must observe the new Grade Group System for prostate cancer 
endorsed by WHO. [56,57]  
 Pathology submitted from elsewhere must be reviewed by centre’s uro-pathologists.  
 There must be expert second opinion available to evaluate the inter-observer 
reproducibility of pathological diagnosis (i.e. for patients enrolled in active 
surveillance), but it is not recommended routinely for prostate cancer.  
3.4.2 Radiology  
Radiology plays a critical role in diagnosing, staging and follow-up of prostate cancer and 
planning of personalised treatment. The role of the radiologist is to perform radiology 
procedures for diagnosis, staging and follow-up using the most appropriate imaging test 




 Radiologists must have expertise in prostate imaging and spend at least 20% of their 
time on urological imaging, including prostate imaging.  
 Radiologists and urologists must know the advantages and limitations of TRUS and 
mpMRI in diagnosis and in primary staging and must be able to integrate imaging 
data in the patient’s clinical context. [58,59,60]  
 As prostate cancer detection and staging is increasingly based mainly on MRI, 
knowledge of state-of-the-art mpMR-protocols, including T2-weighted imaging, 
diffusion weighted imaging and dynamic contrast enhanced imaging is essential. 
Dedicated software tools must be available for quantitative post-processing. 
Standardised reading of MR studies, preferably based on the PI-RADS v2 
classification, must be integrated for reporting and communication with referring 
doctors. [61,62] Expertise in whole body MRI is also essential as it may be needed to 
detect distant metastases, and in particular bone metastases. 
 Radiologists and urologists must be able to perform/participate in targeted biopsies 
(in-bore biopsies) and to perform and/or assist in the preparation and performance of 














 Radiologists must know when to refer a patient to nuclear medicine for PET/CT. 
State-of-the-art CT, MR and PET/CT, including adequate reporting, must be available 
to address specific questions for diagnosis and differential diagnosis. 
 Radiologists must advise on selecting appropriate imaging strategies for patients with 
suspected recurrent prostate cancer.  
 Radiologists must be aware of the potential of radiomics and radiogenomics in 
prostate cancer diagnosis. 
3.4.3 Nuclear medicine  
Nuclear medicine offers a ‘theragnostic’ approach, integrating diagnostics with therapeutics, 
to prostate cancer in certain indications by accurately staging the disease (diagnosis with a 
radiotracer labelled with gamma emitting radionuclides) and applying a non-invasive 
treatment selectively targeting the disease with the same radiotracer. 
There is evidence of the efficacy of PET/CT with prostate-specific radiotracers in these clinical 
indications [65] in which it has demonstrated higher efficacy than CT or MR:  
 Staging of high-risk prostate cancer patients 
 Imaging of biochemical recurrence of prostate cancer patients 
 Imaging of advanced prostate cancer. 
 
In radionuclide therapy, there is evidence of its efficacy in patients with metastatic castration 
resistant prostate cancer with 223Ra (radium-223) [66,67] and 177Lu-PSMA. [68] 
 
There are other clinical situations with limited evidence, but with promising preliminary results: 
 Treatment planning, especially radiation oncology: (a) defining the gross tumour 
volume (GTV); (b) evaluating candidates for boost in biochemical recurrence; and (c) 
confirming probable oligometastatic disease in advanced prostate cancer before 
SBRT (stereotactic body radiation therapy) 
 Guiding biopsies with PET/CT, improving the probability of a successful extraction of 
diagnostic tissue. 
 
The role of the nuclear medicine physician is to oversee all aspects of PET/CT, SPECT/CT 
and radionuclide therapy for patients who require these procedures, including indications, 
multidisciplinary algorithms and management protocols.  
  
Essential requirements 
 PET/CT with prostate-specific radiotracers, SPECT/CT, and radionuclide therapy 
must be available and must be managed by nuclear medicine physicians with the 
appropriate expertise. 
 Nuclear medicine must be able to perform daily verification protocols and to react 
accordingly. Quality assurance protocols must be in place. An option for ensuring the 
high quality of PET/CT scanners is provided by the European Association of Nuclear 
Medicine (EANM) through EARL accreditation.  
 
3.4.4 Urology  
Radical prostatectomy is carried out by urologists for localised prostate cancer, including 
locally advanced disease. EAU-ESTRO-SIOG guidelines state that the goal of radical 
prostatectomy is eradication of prostate cancer while preserving continence and, whenever 
possible, potency. [14] There is no evidence yet that one surgical approach is better than 
another (open, laparoscopic or robotic).  
Surgery for selected patients with oligometastatic and/or recurrent disease is experimental 
and requires a multidisciplinary approach that includes hormone-chemotherapy and/or 
radiation therapy. Focal therapies are also in research stages and are not standards of care. 
[69]  
To be fully competent to perform open radical prostatectomy unsupervised, a surgeon needs 
to perform many more procedures than colleagues performing robotic surgery, which should 
be taken into account when planning services and considering the high cost of robotic 
equipment. [70] 
Urologists also perform ultrasound and biopsy procedures (see radiology), prescribe 















 Two or more urologists trained in prostate cancer diagnosis and treatment must be 
part of the MDT. They must spend at least 50% of their working time on prostate 
cancer care.  
 Urologists must have expertise in performing surgery. Radical prostatectomy can be 
performed by conventional open surgery or by minimal invasive surgery (laparoscopy 
or robotics). The urology department must perform at least 50 radical prostatectomies 
a year.  
 Urology departments must have active surveillance protocols.  
 Urologists must be responsible for follow-up care relating to side-effects of treatment.   
 
3.4.5 Radiation oncology 
Radiation therapy is used as radical primary treatment for all risk groups of prostate cancer 
alone or in combination with adjuvant ADT. It also has a role in the postoperative setting in 
the presence of high-risk features (high Gleason score, locally advanced disease or positive 
margins) or as salvage treatment in case of clinical or biochemical relapse. In patients with 
metastatic disease, EBRT is also used to prevent or reduce symptoms related to metastatic 
localisations (e.g. bone fractures or pain).  
In oligometastatic or oligorecurrent prostate cancer, radiation therapy to the primary site 
and/or the metastases can increase progression-free survival. Newer techniques, such as 
SBRT, especially to metastatic sites, can improve local control while simultaneously 
shortening the treatment duration and thereby reducing the burden for the patient. 
Reported advantages of using current EBRT technologies such as IMRT (intensity modulated 
radiation therapy) include better sexual function and urinary continence than radical 
prostatectomy in localised prostate cancer; [71] and improved bowel function. [72]  
The role of the radiation oncologist (or clinical oncologist in some countries) is to define the 
optimal clinical strategy (dose prescription, appropriate delivery technique, target identification 
and possible association with hormones). Radiation oncologists may also take responsibility 
for supervising and administering radionuclide therapy in collaboration with the nuclear 
medicine department. 
  
Essential requirements  
 Radiation therapy must be provided within the prostate cancer centre or at a radiation 
oncology department via formal agreement.  
 Radiation oncologists must have adequate experience in contemporary radiation 
therapy techniques that are accredited for quality, including the technical aspects of 
radiation delivery dose. 
 Radiation therapy options must include IMRT and IGRT with CT and MR based target 
volume and organ at-risk definition and contouring. 
 EBRT for primary radical treatment must be given in conjunction with ADT except in 
low risk cases and selected intermediate risk disease. 
 Protocols must be in place to define evidence-based dose fractionation schedules for 
both radical and palliative treatment. Reimbursement issues must be addressed 
concerning the use of inappropriately protracted radiation schedules.  
 There must be access to both low dose rate and high dose rate brachytherapy in the 
treating centre or by formal agreement with neighbouring centres. A minimum of 25 
cases per year must be undertaken by a radiation oncologist performing 
brachytherapy to maintain expertise. [73] 
 The radiation oncologist must be responsible for individualised follow-up to evaluate 
radiation-affected bowel, urinary and sexual function, with access to specialist teams.  
 
3.4.6 Medical oncology  
 
Medical oncologists, or clinical oncologists in certain countries, deliver medical therapy. 
Medical therapy for prostate cancer includes hormonal therapies and intravenous 
chemotherapy (e.g. docetaxel, mitoxantrone, cabazitaxel). Docetaxel can be used in 
combination with ADT in patients with 1st line metastatic castration naive prostate cancer. 
Chemotherapy is also used later in the disease course (in the castration resistant setting) for 













Oral second-generation hormonal therapy (e.g. abiraterone, enzalutamide) is used for 
patients with metastatic castrate-resistant prostate cancer who have failed on prior hormone 
therapy or chemotherapy. [74,75,76] Recent data suggests that abiraterone may be used 
increasingly in the initial treatment of patients with hormone-naïve prostate cancer. [77] 
Systemic chemotherapy and second-generation hormonal therapies are often given together 
with bone protecting agents such as bisphosphonates or denosumab. [78,79] Radium-223 
must be available for the treatment of metastatic bone disease. 
 
Essential requirements 
 Medical or clinical oncologists must be experienced in the evaluation of patients with 
prostate cancer, and in the delivery of systemic therapy. They must evaluate 
patients for their fitness to receive systemic treatment taking account of comorbidity, 
frailty and patient preference. 
 At least two medical or clinical oncologists must be associated with each MDT such 
that one is present at all team meetings and party to all decisions about appropriate 
patients.  
 A medical or clinical oncologist who is specialised in the management of prostate 
cancer must spend at least 25% of their time working on the care of prostate cancer 
patients or on supporting activities in service development and research that are an 
important part of prostate cancer care. 
 Medical or clinical oncologists must also be familiar with the complex initial 
investigations of prostate cancer, which underpin decisions that are taken about 
primary surgery, radiation therapy, combined modality therapy or active 
surveillance. 
 They must know toxicities and long-term adverse effects of treatments, such as 
osteoporosis, metabolic syndrome, muscle strength impairment, hot flashes, and 
sexual dysfunction due to castration and engage with the extended MDT to provide 
supportive care.  
 They must be trained in palliative care and experienced in working with specialists in 
palliative care and pain control.  
 
3.4.7 Nursing 
Nurses provide information, care and support to men and their families with prostate cancer 
throughout the patient pathway. Nurses are a key contact for patients, provide information to 
facilitate informed decision-making for treatment options, [80] undertake holistic needs 
assessment, and help manage symptoms such as urinary incontinence.  
Across Europe there is a wide geographic variation in access to prostate cancer nurses. 
Some countries have developed specialist nurse roles such as urology, uro-oncology, and 
prostate cancer nurse specialists, and cancer navigators. Others have advanced nurse 
practitioner roles who carry out prostate biopsy, caseload management, nurse-led follow-up, 
assessment and management of treatment related toxicity including nurse prescribing, 
survivorship and rehabilitation programmes. However, few nurses in Europe are currently 
dedicated to prostate cancer care, but it is likely they will at least play a pivotal role as case 
managers in MDTs. [81]  
A European study has identified the prevalence of unmet needs of men and the impact that 
supportive nursing can have. [82] There is also a role for community prostate cancer nurses 
who help to look after men who have adverse consequences from their treatment, such as 
incontinence. Findings from a pilot trial of nurse-led psycho-educational intervention in 




 Nurses must have training to have detailed insight into each patient’s experience on 
the stages of their disease, proposed treatment and side-effects. 
 Nurses must conduct holistic assessments to ensure safe, personalised and age-
appropriate nursing care, and provide patient information and support that promotes 
self-efficacy throughout the patient journey. Validated instruments (e.g. a ‘distress 
thermometer’) and symptom assessment tools must be used where appropriate and 













 Nursing interventions must be optimised to minimise side-effects and to maximise 
treatment benefit and quality of life, in surgery (e.g. wound healing), radiation therapy 
(e.g. bowel and urinary effects), chemotherapy (e.g. neutropenia, sepsis), ADT (hot 
flushes, metabolic syndrome, osteopenia/osteoporosis, erectile dysfunction, loss of 
libido) and in clinical trials. Fatigue is often mentioned by patients and must be 
considered by nurses.  
 When performing advanced nursing roles (e.g. case manager, nurse navigator, 
clinical nurse specialist), nurses must coordinate care with healthcare professionals 
within and outside the core MDT, including with rehabilitation, psychosocial and 
palliative care services. 
 Health systems must consider establishing community prostate cancer care facilities 
and nurses to ease demands on the acute sector and bring holistic care closer to 
where men live.[84]  
 
 
3.5 Disciplines in the extended MDT 
 
3.5.1 Geriatric oncology 
The MDT must have access to geriatricians with oncology experience, or specialist geriatric 
oncologists. Older patients with prostate cancer require special attention to ensure they are 
not over- or undertreated; guidelines on the management of patients over 70 state that 
treatment decisions should not be based on chronological age but on patient’s general health 
and patient preference.  
The role of the geriatrician is to coordinate recommendations to other specialists about the 
need for personalised treatment for older patients with increased vulnerability and frailty. 




 All older patients (70+) must be screened with a quick, simple frailty screening tool, 
such as the adapted Geriatric-8 (G8) screening tool. [88] 
 Frail and disabled patients must undergo a geriatric assessment. [89] The 
assessment can be based on self-report combined with objective assessments that 
can be performed by a specialist nurse in collaboration with a physician 
(geriatrician/specialist in internal medicine).  
 Cognitive impairment affects all aspects of treatment – ability to consent, compliance 
with treatment, and risk of delirium – and screening using tools such as Mini-Cog [90] 
is essential. A geriatrician or a geriatric psychiatrist or neurologist would preferably be 
involved with impaired patients. 
 For frail and disabled patients, the geriatrician or specialist nurse must be present in 
the MDT meeting to discuss treatment options aligned with the patient’s goals of care. 
 
3.5.2 Oncology pharmacy  
The complexity and often low safety profile of oncology drugs together with the high cost of 
drugs involved in prostate cancer treatment means that it is essential to optimise 
pharmacotherapy. Oncology pharmacy plays a critical role in the extended MDT in the care of 
prostate cancer patients, given the importance of systemic treatment.  
The role of the oncology pharmacist is to: 
 Liaise with the medical oncologist/clinical oncologist/uro-oncologist to discuss cancer 
specific treatments, including interactions with other treatments  
 Counsel patients about their drug treatment 
 Supervise the preparation of oncology drugs.  
Essential requirements 
 Oncology pharmacists must have experience with antineoplastic treatments and 
supportive care; interactions between drugs; drug dose adjustments based on age, 
liver and kidney function, and toxicity profile; utilisation and monitoring of 
pharmacotherapy; patient counselling and pharmacovigilance; and knowledge of 
complementary and alternative medicines.  
 Oncology pharmacists must comply with the European Quality Standard for the 














pharmacy and dispensing must take place under the supervision of the oncology 
pharmacist.  
 Oncology pharmacists must provide personalised information for patients on their 
drug therapy to support adherence, i.e. on the use of new oral drugs such as 
abiraterone and enzalutamide. 




3.5.3 Psycho-oncology  
About 10%–23% of prostate cancer patients report clinically significant distress; [92] 
symptoms of distress can continue into survivorship. Common reactions include excessive 
worry and rumination, difficulty concentrating, insomnia, increased use of alcohol and other 
drugs, social withdrawal and somatic complaints. There is strong evidence that psychological 
interventions can improve psychological outcomes; however, in prostate cancer a systematic 
review of psychosocial interventions did not find sufficiently strong evidence to permit 
meaningful conclusions, and additional well-executed and transparently reported research 
studies are necessary. [93]  
  
The role of the psycho-oncologist is to: 
 Ensure that psychosocial distress, [94] and other psychological disorders and 
psychosocial needs, are identified by screening throughout the disease continuum, 
and are considered by the MDT 
 Promote effective communication between patients, family members and 
healthcare professionals 




 Patients must have access to a self-administered psychological assessment tool 
(‘distress thermometer’). Scores below a certain level must be routinely managed by 
the primary care team; above that level there must be further clinical interviewing and 
screening for anxiety and depression, and referral to the most appropriate 
professional, such as a mental health physician. 
 Psychosocial care must be provided at all stages of the disease and its treatment for 
patients and their partners [95] and families and must be present to ensure 
comprehensive cancer care. 
 Psychosocial interventions must be based on clinical practice guidelines or the NCCN 




Physiotherapy plays a role in interventions that can help to preserve and restore continence 
after prostatectomy and that address erectile dysfunction. Evidence suggests that urinary 
incontinence, fitness, fatigue, body constitution and quality of life can all be improved by 
exercise in patients during and after prostate cancer. [96,97] 
Essential requirement 
 A physiotherapist trained in incontinence and erectile dysfunction management in 
men with prostate cancer must be available to the core MDT when needed before 
and after radical treatment.  
3.5.5 Palliative care 
Palliative care, as defined by the World Health Organization, applies not only at end of life, 
but throughout cancer care (http://www.who.int/cancer/palliative/definition). Palliative care 
means patient and family centred care that enhances quality of life by preventing and treating 
physical, psychosocial and spiritual suffering. [98,99] 
 
There is an increasing need for palliative care services for prostate cancer patients 
throughout the disease trajectory in conjunction with standard cancer treatments, as a 
majority of prostate cancer patients are older men. Endocrine treatments for prostate cancer 














In patients with advanced disease the most common metastases are skeletal with significant 
symptoms such as pain and fatigue albeit with relatively long survival.[100,101] 
 
Palliative care services include general palliative care provided by oncology professionals and 
other clinicians who are responsible for cancer care, and specialised care provided by a 
multidisciplinary palliative care team. [102,103] Referral to a specialised palliative care team 
should be offered early in the disease course concurrently with cancer treatment for all 
patients with newly diagnosed advanced disease and for patients with high symptom burden 
or unmet physical or psychosocial needs. [104]  
 
Essential requirements  
 There must be access to a dedicated palliative care unit with a specialised palliative 
care team that provides expert outpatient and inpatient care.  
 All cancer patients with severe symptoms or suffering, or patients with incurable 
disease, must be introduced to the specialist palliative care team, irrespective of the 
cancer-specific treatment plan. 
 The palliative care team must include palliative care physicians and specialist nurses, 
working with an extended team of social workers, chaplains, psychotherapists, 
physiotherapists, occupational therapists, dieticians, pain specialists and psycho-
oncologists.  
 The specialised palliative care team must have good knowledge of cancer and its 
treatment including palliative radiation therapy and isotope therapy of bone 
secondaries, adverse effects of treatment, i.e. castration related symptoms and 
rehabilitation needs of patients, to offer holistic care in collaboration with other 
professionals. 
 The palliative care team must have experience of taking care of frail older patients 
and their families.  
 To ensure the continuity of care at home, the palliative care team must work with 
community/primary care providers. 
 Palliative care specialists and oncologists must aspire to meet the standards of the 




3.5.6 Sexual rehabilitation 
Radical prostatectomy, especially, can profoundly affect sexual functioning. Sexual 
rehabilitation can be provided by specialist therapists and counsellors, who may have a 
background in medicine, nursing or psychology, and also by urologists and andrologists 
trained in sex therapy.  
Rehabilitation after prostate cancer surgery mainly focuses on restoring erectile function 
through various means (drugs, gel, intracavernous injection, mechanical devices), but there is 
a view that more comprehensive sexual rehabilitation should be included that also addresses 
other side-effects of surgery such as loss of ejaculate, penile shortening, change of orgasmic 
feeling, alterations in body image, stress incontinence, disturbances in partner relationships 




 There must be a professional specialising in comprehensive clinical sexual 
rehabilitation available to surgical prostate cancer patients as part of the extended 














4 Other essential requirements  
 
4.1 Patient involvement, access to information and transparency 
 
 Patients must be involved in every step of the decision-making process and their 
satisfaction with their care must be assessed throughout the patient care pathway. 
Patients and their families and carers must be offered relevant, objective and 
understandable information, which may include decision support aids, to help them 
appreciate the process that will be followed with their treatment from the point of 
diagnosis. They must be supported and encouraged to engage with their health team 
to ask questions and obtain feedback on their treatment wherever possible. 
 It is also essential that prostate cancer patient support organisations are involved 
whenever relevant throughout the patient pathway. These groups work to:  
– Improve patients’ knowledge and ability to take decisions 
– Secure access to innovative therapies and improve quality of treatment 
– Support prostate cancer research, such as by being involved in the better design 
of clinical trials 
– Advocate at national health policy level. 
Patient advocacy for prostate cancer has improved greatly in the past 10 years or so. 
Europa Uomo, [106] the European Prostate Cancer Coalition, was established in 
2002 and now has 23 member organisations across Europe (https://www.europa-
uomo.org). Some member organisations are also federations of support groups in a 
country – for example, in the UK Tackle Prostate Cancer 
(http://www.tackleprostate.org) has dozens of local support groups listed on its site, 
and also partner organisations such as Prostate Cancer UK 
(https://prostatecanceruk.org).  
 Conclusions on each case discussion must be made available to patients and their 
primary care physician. Advice on seeking second opinions must be supported. 
 Cancer healthcare providers must publish on a website, or make available to patients 
on request, data on centre/unit performance, including:  
– Information services 
– Waiting times to first appointment 
– Pathways of cancer care 
– Numbers of patients and treatments available at the centre  
– Number of operated patients at the centre (per procedure)  
– Clinical trials. 
 
The ERQCC expert group also recommends that the following are made public: 
– Clinical outcomes  
– Patient reported outcomes 




4.2 Performance and quality  
 
The prostate cancer centre must develop: 
 Performance measurement metrics/quality indicators based on the essential 
requirements in this paper and on clinical guidelines 
 Operational policies to ensure the full benefits of a coordinated clinical pathway 
based on published guidelines 
 Accountability within the governance processes in individual institutions  
 Systems to ensure safe and high-quality patient care and experience throughout the 
clinical pathway 
 Effective data management and reporting systems 
 Engagement with patients, their carers and support groups to ensure reporting of 
patient outcomes and experience. 
 
To assess properly the quality of prostate cancer care, three categories of outcomes must be 
measured and collected in databases at the level of the specialist centre, regionally and/or 
nationally: 














 Process outcomes  
 Patient reported outcomes. 
 
This includes national audits where available and national cancer registration/certification. 
These approaches can be developed in the context of quality management systems (QMS) 
depending on the health economy of an individual country. The benefits of such a system 
include: 
 Improving processes to enhance patient safety 
 Setting standards within a clinical pathway 
 Ensuring appropriate resource management including workforce and financial 
resources 
 Facilitating training opportunities 
 Determining optimal outcomes with appropriate audit. 
 
4.2.1 Audit  
Data measured and collected varies among countries, but it is recommended that these 
outcome metrics are systematically measured and collected for audit: 
 % of patients discussed by the MDT prior to treatment 
 % of patients discussed by the MDT after (surgical) treatment 
 % of patients according to clinical stage at time of diagnosis  
 % of patients showing biochemical/clinical failure after radical treatments discussed 
by the MDT 
 % of patients receiving treatment with curative and palliative intent 
 Volume of specific curative procedures, such as radical prostatectomy and radiation 
therapy 
 Complications and toxicities 
 In-hospital mortality 
 1 and 5-year overall survival rate 
 Adherence to MDT recommendations. 
 
4.2.2 MDT performance  
 All MDT decisions must be documented in an understandable manner, and must 
become part of patient records. Decisions taken during MDT meetings must be 
monitored, and deviations reported back to the MDT. It is essential that all relevant 
patient data, such as pathology reports, meet quality standards and are available at 
the time of the MDT meeting.  
 The core and extended MDTs must meet at least twice a year to review the activity of 
the previous period based on the audited metrics, discuss changes in protocols and 
procedures, and improve the performance of the unit/centre. MDT performance must 
be quality assured both internally and by external review with demonstration of cost-
effectives of quality improvements, and MDT guidance must be promoted nationally 
and written into national cancer plans.  
 The ERQCC expert group strongly recommends that further attention must be given 
to measures of patient reported outcomes, not only to agree which tools should be 
used, but also to use such outcomes more systematically as part of discussions and 
evaluation within the MDT. 
 
4.2.3 Accreditation 
The ERQCC expert group strongly recommends participation in national or international 
accreditation programmes, e.g. Organisation of European Cancer Institutes (OECI) 



















5 Education and training  
 
It is essential that each prostate cancer centre provides professional clinical and scientific 
education on the disease and that at least one person is responsible for this programme. 
Healthcare professionals working in prostate cancer must also receive training in 
psychosocial oncology, palliative care, rehabilitation and communication skills. Such training 
must also be incorporated into specialist postgraduate and undergraduate curriculums for 
physicians, nurses and other professionals. An expert group on cancer control of the 
European Commission has also endorsed a recommendation for multidisciplinary training of 
cancer specialists to improve the value of MDTs and patient care. [108] Nurses should 
undertake post-qualification education and training about providing holistic care for people 
being treated for prostate cancer throughout the patient journey.  
 
 
6 Clinical research and registries 
 
 Centres treating prostate cancer must have clinical research programmes (either their 
own research or as a participant in programmes led by other centres). The research 
portfolio should have both interventional and non-interventional projects and include 
academic research. The MDT must assess all new patients for eligibility to take part 
in academic and industry sponsored clinical trials at the centre or in research 
networks. Research must encompass not only advanced prostate cancer but also 
localised disease and identification of clinically significant prostate cancer.  
 The German Cancer Society specifies a minimum accrual rate for clinical trials of 5% 
and the OECI requirement for CCCs is >10%. The ERQCC expert group considers 
that the 5% target is an important recommendation for all prostate units.  
 Collaboration with European academic networks is strongly recommended – see the 
genito-urinary cancer groups of the European Organisation for Research and 
Treatment of Cancer (EORTC – http://www.eortc.org), the European Clinical 
Research Infrastructure Network (ECRIN – http://www.ecrin.org), and the EAU 
Research Foundation (http://uroweb.org/research/about). 
 In countries where clinical trials are less available, centres treating prostate cancer 
should engage with policymakers to investigate referring patients to other countries 
(as proposed with European Reference Networks) and should be prepared to 
participate in clinical trials from an organisational standpoint. Researchers at other 
centres should be considered as part of the extended MDT for at least annual 
discussion of clinical trial participation. Generally, pan-European action should be 
taken to increase participation of prostate cancer patients in clinical trials (both 
industry-sponsored and academic), and internet access to local clinical trial 
databases should be developed. 
 Older adults are currently underrepresented in cancer clinical trials despite having a 
disproportionate burden of disease. Strategies to increase the participation of older 
adults must be implemented and trials designed to take their needs into account. 
 Correlative biomarker research is a crucial part of all phases of clinical studies, and 
requires close cooperation with biobanks such as EORTC’s SPECTA programme 
(http://www.eortc.org/other-research-initiatives/specta).  
 Cancer control plans must include high-quality population and specialist cancer 
registries for prostate cancer to inform both clinical research and to improve the 
quality of care through indicators. At population level, the Association of Nordic 
Cancer Registries includes prostate cancer in 50 cancer types in the Nordic countries 
(https://www.ancr.nu). Sweden’s National Quality Registry for Prostate Cancer 
(NPCR) is notable as it collects data on diagnosis and how tumours were assessed, 
treatment and waiting times, and patient-reported symptoms up to 5 years after 
treatment, and is said to be the world’s largest clinical database on prostate cancer 
(http://npcr.se). PcBaseSweden is a research platform based on NPCR. [109] The 
TrueNTH Global Registry project has recently been established as an international 






















The information presented in this paper is a description of the essential requirements for a 
high-quality prostate cancer service. The ERQCC expert group is aware that it is not possible 
to propose a ‘one size fits all’ system for all countries, but urges that access to MDTs and 
specialised treatments is guaranteed to all patients with prostate cancer in Europe. 
 
Conflict of interest statement 
 




[1] Højgaard, L., Löwenberg, B., Selby, P., Lawler, M., Banks, I., Law, K., et al., 2017. The European Cancer Patient’s Bill of Rights, 
update and implementation 2016. ESMO Open 1 (6), e000127. https://doi.org/10.1136/esmoopen-2016-000127. 
[2] Albreht, T., Kiasuma, R., Van den Bulcke, M., 2017. Cancon Guide – Improving cancer control coordination. 
https://cancercontrol.eu/archived/cancercontrol.eu/guide-landing-page/index.html. 
[3] Prades, J., Remue, E., van Hoof, E., Borras, J.M., 2015. Is it worth re-organising cancer services on the basis of multidisciplinary 
teams (MDTs)? A systematic review of the objectives and organisation of MDTs and their impact on patient outcomes. Health Policy 
119 (4), 464–474. http://dx.doi.org/10.1016/j.healthpol.2014.09.006. 
[4] Borras, J.M., Albreht, T., Audisio, R., Briers, E., Casali, P., Esperou, H., et al., 2014. Policy statement on multidisciplinary cancer 
care. Eur. J. Cancer 50 (3), 475–480. https://doi.org/10.1016/j.ejca.2013.11.012. 
[5] Cardoso, F., Cataliotti, L., Costa, A., Knox, S., Marotti, L., Rutgers, E., et al., 2017. European Breast Cancer Conference manifesto 
on breast centres/units. Eur. J. Cancer 72, 244–250. http://dx.doi.org/10.1016/j.ejca.2016.10.023. 
[6] Valdagni, R., Albers, P., Bangma, C., Drudge-Coates, L., Magnani, T., Moynihan, C., et al., 2011. The requirements of a specialist 
prostate cancer unit: a discussion paper from the European School of Oncology. Eur. J. Cancer 47 (1), 1–7. 
https://doi.org/10.1016/j.ejca.2010.10.029. 
[7] Valdagni, R., Van Poppel, H., Aitchison, M., Albers, P., Berthold, D., Bossi, A., et al., 2015. Prostate Cancer Unit Initiative in 
Europe: a position paper by the European School of Oncology. Crit. Rev. Oncol. Hematol. 95 (2), 133–143. 
https://doi.org/10.1016/j.critrevonc.2015.05.014. 
[8] Wirth, M., Fossati, N., Albers, P., Bangma, C., Brausi, M., Comperat, E., et al., 2019. The European Prostate Cancer Centres of 
Excellence: a novel proposal from the European Association of Urology prostate cancer centre consensus meeting. Eur. Urol. pii: 
S0302-2838(19)30077-6. https://doi.org/10.1016/j.eururo.2019.01.033. 
[9] European Cancer Information System. https://ecis.jrc.ec.europa.eu/index.php. 
[10] Trama, A., Foschi, R., Larrañaga, N., Sant, M., Fuentes-Raspall, R., Serraino, D., et al., 2015. Survival of male genital cancers 
(prostate, testis and penis) in Europe 1999-2007: Results from the EUROCARE-5 study. Eur. J. Cancer 51 (15), 2206–2216. 
https://doi.org/10.1016/j.ejca.2015.07.027. 
[11] Cancer Research UK. Prostate cancer survival statistics. https://bit.ly/2RmmriO. 
[12] International Agency for Research on Cancer (IARC), 2012. Study finds prostate cancer increasing in most countries. Press 
release no. 209. https://www.iarc.fr/en/media-centre/pr/2012/pdfs/pr209_E.pdf. 
[13] Cuzick, J., Thorat, M.A., Andriole, G., Brawley, O.W., Brown, P.H., Culig, Z., et al. 2014. Prevention and early detection of 
prostate cancer. Lancet Oncol. 15 (11), e484–e492. https://doi.org/10.1016/S1470-2045(14)70211-6. 
[14] Mottet, N., Bellmunt, J., Bolla, M., Briers, E., Cumberbatch, M.G., De Santis, M., et al., 2017. EAU-ESTRO-SIOG Guidelines on 
Prostate Cancer. Part 1: Screening, diagnosis, and local treatment with curative intent. Eur. Urol. 71 (4), 618–629, 
https://doi.org/10.1016/j.eururo.2016.08.003.  
[15] National Institute of Health and Care Excellence (NICE), 2014. Prostate cancer: diagnosis and management. Clinical guideline 
[CG175]. https://www.nice.org.uk/guidance/cg175. 
[16] Ahmed, H.U., El-Shater Bosaily, A., Brown, L.C., Gabe, R., Kaplan, R., Parmar. M.K., et al., 2017. Diagnostic accuracy of multi-
parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet 389 (10071), 815–822. 
https://doi.org/10.1016/S0140-6736(16)32401-1. 
[17] Kasivisvanathan, V., Rannikko, A.S., Borghi, M., Panebianco, V., Mynderse, L.A., Vaarala, M.H., et al., 2018. MRI-targeted or 
standard biopsy for prostate-cancer diagnosis. N. Engl. J. Med. 378 (19), 1767–1777. https://doi.org/10.1056/NEJMoa1801993. 
[18] Kratzenberg, J., Salomon, G., Tennstedt, P., Dell’Oglio, P., Tilki, D., Haferkamp, A., et al., 2018. Prostate cancer rates in patients 
with initially negative elastography-targeted biopsy vs. systematic biopsy. World J. Urol. 36 (4), 623–628. 
https://doi.org/10.1007/s00345-018-2178-x. 
[19] Kuru, T.H., Fütterer, J.J., Schiffmann, J., Porres, D., Salomon, G., Rastinehad, A.R., 2015. Transrectal ultrasound (US), contrast-
enhanced US, real-time elastography, histoscanning, magnetic resonance imaging (MRI), and MRI-US fusion biopsy in the diagnosis 
of prostate cancer. Eur. Urol. Focus 1 (2), 117–126. https://doi.org/10.1016/j.euf.2015.06.003. 
[20] Cornford, P., Bellmunt, J., Bolla, M., Briers, E., De Santis, M., Gross, T., et al, 2017. EAU-ESTRO-SIOG Guidelines on Prostate 
Cancer. Part II: Treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur. Urol. 71 (4), 630–642. 
https://doi.org/10.1016/j.eururo.2016.08.002. 
[21] Tosoian, J.J., Gorin, M.A., Ross, A.E., Pienta, K.J., Tran, P.T., Schaeffer, E.M., 2017. Oligometastatic prostate cancer: definitions, 
clinical outcomes, and treatment considerations. Nat. Rev. Urol. 14 (1), 15–25. https://doi.org/10.1038/nrurol.2016.175. 
[22] Ost, P., Reynders, D., Decaestecker, K., Fonteyne, V., Lumen, N., De Bruycker, A., et al., 2018. Surveillance or metastasis-
directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J. Clin. Oncol. 
36 (5), 446–453. https://doi.org/10.1200/JCO.2017.75.4853.  
[23] Schröder, F.H., Hugosson, J., Roobol, M.J., Tammela, T.L., Ciatto, S., Nelen, V., et al., 2009. Screening and prostate-cancer 
mortality in a randomized European study. N. Engl. J. Med. 360 (13), 1320–1328. https://doi.org/10.1056/NEJMoa0810084. 
[24] Andriole, G.L., Crawford, E.D., Grubb, R.L. 3rd., Buys, S.S., Chia, D., Church, TR., et al., 2009. Mortality results from a 
randomized prostate-cancer screening trial. N. Engl. J. Med. 360 (13), 1310–1319. https://doi.org/10.1056/NEJMoa0810696. 
[25] Tsodikov, A., Gulati, R., Etzioni, R., 2018. Reconciling the effects of screening on prostate cancer mortality in the ERSPC and 












[26] Martin, R.M., Donovan, J.L., Turner, E.L., Metcalfe, C., Young, G.J., Walsh, E.I., et al., 2018. Effect of a low-intensity PSA-based 
screening intervention on prostate cancer mortality: the CAP randomized clinical trial. JAMA 319 (9), 883–895. 
https://doi.org/10.1001/jama.2018.0154. 
[27] Swann, R., McPhail, S., Witt, J., Shand, B., Abel, G.A., Hiom, S., et al., 2018. Diagnosing cancer in primary care: results from the 
National Cancer Diagnosis Audit. Br. J. Gen. Pract. 68 (666), e63–e72. https://doi.org/10.3399/bjgp17X694169. 
[28] Sundi, D., Cohen, J.E., Cole, A.P., Neuman, B.P., Cooper, J., Faisal, F.A., et al., 2015. Establishment of a new prostate cancer 
multidisciplinary clinic: format and initial experience. Prostate 75 (2), 191–199. https://doi.org/10.1002/pros.22904. 
[29] Schroeck, F.R., Jacobs, B.L., Hollenbeck, B.K., 2013. Understanding variation in the quality of the surgical treatment of prostate 
cancer. Am. Soc. Clin. Oncol. Educ. Book 278–83. https://doi.org/10.1200/EdBook_AM.2013.33.278. 
[30] Wallis, C.J.D., Morton, G., Herschorn, S., Kodama, R.T., Kulkarni, G.S., Appu, S., et al., 2018. The effect of selection and referral 
biases for the treatment of localised prostate cancer with surgery or radiation. Br. J. Cancer 118 (10), 1399–1405. 
https://doi.org/10.1038/s41416-018-0071-4. 
[31] Jang, T.L., Bekelman, J.E., Liu, Y., Bach, P.B., Basch, E.M., Elkin, E.B., et al., 2010. Physician visits prior to treatment for 
clinically localized prostate cancer. Arch. Intern. Med. 170 (5), 440–450. https://doi.org/10.1001/archinternmed.2010.1. 
[32] Patrikidou, A., Maroun, P., Patard, J.J., Baumert, H., Albiges, L., Massard, C., 2018. Helping patients make informed decisions. 
Two-year evaluation of the Gustave Roussy prostate cancer multidisciplinary clinic. Clin. Transl. Radiat. Oncol. 12, 28–33. 
https://doi.org/10.1016/j.ctro.2018.07.001. 
[33] Gomella, L.G., Lin, J., Hoffman-Censits, J., Dugan, P., Guiles, F., Lallas, C.D., 2010. Enhancing prostate cancer care through the 
multidisciplinary clinic approach: a 15-year experience. J. Oncol. Pract. 6 (6), e5–e10. https://doi.org/10.1200/JOP.2010.000071. 
[34] Aizer, A.A., Paly, J.J., Zietman, A.L., Nguyen, P.L., Beard, C.J., Rao, S.K., 2012. Multidisciplinary care and pursuit of active 
surveillance in low-risk prostate cancer. J. Clin. Oncol. 30 (25), 3071–3076. https://doi.org/10.1200/JCO.2012.42.8466. 
[35] Feldman-Stewart, D., Tong, C., Brundage, M., Bender, J., Robinson, J., 2018. Making their decisions for prostate cancer 
treatment: patients' experiences and preferences related to process. Can. Urol. Assoc. J. 12 (10). https://doi.org/10.5489/cuaj.5113. 
[36] Thurtle, D.R., Greenberg, D.C., Lee, L.S., Huang, H.H., Pharoah, P.D., Gnanapragasam, V.J., 2019. Individual prognosis at 
diagnosis in nonmetastatic prostate cancer: Development and external validation of the PREDICT prostate multivariable model. PLoS 
Med. 16 (3), e1002758. https://doi.org/10.1371/journal.pmed.1002758. 
[37] Chambers, S.K., Hyde, M.K., Smith, D.P., Hughes, S., Yuill, S., Egger, S., et al., 2017. New challenges in psycho-oncology 
research III: A systematic review of psychological interventions for prostate cancer survivors and their partners: clinical and research 
implications. Psychooncology 26 (7), 873–913. https://doi.org/10.1002/pon.4431. 
[38] Paterson, C., Robertson, A., Smith, A., Nabi, G., 2015. Identifying the unmet supportive care needs of men living with and beyond 
prostate cancer: a systematic review. Eur. J. Oncol. Nurs. 19 (4), 405–418. https://doi.org/10.1016/j.ejon.2014.12.007. 
[39] Smith, D.P., King, M.T., Egger, S., Berry, M.P., Stricker, P.D., Cozzi, P., et al., 2009. Quality of life three years after diagnosis of 
localised prostate cancer: population based cohort study. BMJ 339, b4817. https://doi.org/10.1136/bmj.b4817. 
[40] Giri, V.N., Gross, L., Gomella, L.G., Hyatt, C., 2016. How I do it: Genetic counseling and genetic testing for inherited prostate 
cancer. Can. J. Urol. 23 (2), 8247–8253. https://www.ncbi.nlm.nih.gov/pubmed/27085833. 
[41] Pritchard, C.C., Mateo, J., Walsh, M.F., De Sarkar, N., Abida, W., Beltran, H., et al., 2016. Inherited DNA-repair gene mutations in 
men with metastatic prostate cancer. N. Engl. J. Med. 375 (5), 443–53. https://doi.org/10.1056/NEJMoa1603144. 
[42] Zhen, J.T., Syed, J., Nguyen, K.A., Leapman, M.S., Agarwal, N., Brierley, K., et al., 2018. Genetic testing for hereditary prostate 
cancer: current status and limitations. Cancer 124 (15), 3105–3117. https://doi.org/10.1002/cncr.31316. 
[43] Giri, V.N., Knudsen, K.E., Kelly, W.K., Abida, W., Andriole, G.L., Bangma, C.H., et al., 2018. Role of genetic testing for inherited 
prostate cancer risk: Philadelphia Prostate Cancer Consensus Conference 2017. J. Clin. Oncol. 36 (4), 414–424. 
https://doi.org/10.1200/JCO.2017.74.1173. 
[44] Vernooij, R.W.M., van Oort, I., de Reijke, T.M., Aben, K.K.H., 2019. Nationwide treatment patterns and survival of older patients 
with prostate cancer. J. Geriatr. Oncol. 10 (2), 252–258. https://doi.org/10.1016/j.jgo.2018.06.010. 
[45] Trama, A., Botta, L., Nicolai, N., Rossi, P.G., Contiero, P., Fusco, M., et al., 2016. Prostate cancer changes in clinical presentation 
and treatments in two decades: an Italian population-based study. Eur. J. Cancer 67, 91–98. 
https://doi.org/10.1016/j.ejca.2016.07.021. 
[46] Berglund, A., Garmo, H., Robinson, D., Tishelman, C., Holmberg, L, Bratt, O., et al., 2012. Differences according to 
socioeconomic status in the management and mortality in men with high risk prostate cancer. Eur J. Cancer 48 (1), 75–84. 
https://doi.org/10.1016/j.ejca.2011.07.009. 
[47] Aarts, M.J., Koldewijn, E.L., Poortmans, P.M., Coebergh, J.W., Louwman, M., 2013. The impact of socioeconomic status on 
prostate cancer treatment and survival in the southern Netherlands. Urology 81 (3), 593–599. 
https://doi.org/10.1016/j.urology.2012.11.011. 
[48] European Partnership for Action Against Cancer (EPAAC). European Guide for Quality National Cancer Control Programmes. 
p31. http://www.epaac.eu/images/WP_10/European_Guide_for_Quality_National_Cancer_Control_Programmes_EPAAC.pdf. 
[49] Jallad, S., Hounsome, L., Verne, J., Mayer, E., 2017. Where are we with improving outcome guidance? An update on pelvic 
urological services in the NHS. J. Clin. Urol. 10 (1_suppl), 29–33. https://doi.org/10.1177%2F2051415816664272. 
[50] German Cancer Society (DKG). Annual report 2017 of the certified prostate cancer centres. 
https://www.krebsgesellschaft.de/gcs/german-cancer-society/certification/documents.html. 
[51] Almatar, A., Wallis, C.J., Herschorn, S., Saskin, R., Kulkarni, G.S., Kodama, R.T., et al., 2016. Effect of radical prostatectomy 
surgeon volume on complication rates from a large population-based cohort. Can. Uro. Assoc. J. 10 (1-2), 45–49. 
https://doi.org/10.5489/cuaj.3214. 
[52] Trinh, Q.D., Bjartell, A., Freedland, S.J., Hollenbeck, B.K., Hu, J.C., Shariat, S.F., et al., 2013. A systematic review of the volume-
outcome relationship for radical prostatectomy. Eur. Urol. 64 (5), 786–798. https://doi.org/10.1016/j.eururo.2013.04.012. 
[53] Leow, J.J., Leong, E.K., Serrell, E.C., Chang, S.L., Gruen, R.L., Png, K.S., et al., 2017. Systematic review of the volume-outcome 
relationship for radical prostatectomy. Eur. Urol. Focus pii: S2405–4569(17)30076-7. https://doi.org/10.1016/j.euf.2017.03.008. 
[54] SONCOS, 2017. Standardisation of Multidisciplinary Care in the Netherlands. SONCOS Standardisation Report 5. 
https://www.soncos.org/wp-content/uploads/2017/10/46SONCOS-standardisation-report.pdf. 
[55] Kench, J.G., Egevad, L., Delahunt, B., Humphrey, P.A., Kristiansen, G., Oxley, J.D., et al., 2017. Prostate Cancer, Transurethral 
Resection and Enucleation, Histopathology Reporting Guide 1st edition. International Collaboration on Cancer Reporting; Sydney, 
Australia. ISBN: 978-1-925687-06-4. 
[56] Epstein, J.I., Egevad, L., Amin, M.B., Delahunt, B., Srigley, J.R., Humphrey, P.A., et al., 2016. The 2014 International Society of 
Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: definition of grading patterns and 
proposal for a new grading system. Am. J. Surg. Pathol. 40 (2), 244–252. https://doi.org/10.1097/PAS.0000000000000530. 
[57] Epstein, J.I., Amin, M.B., Reuter, V.E., Humphrey, P.A., 2017. Contemporary Gleason Grading of prostatic carcinoma: an update 
with discussion on practical issues to implement the 2014 International Society of Urological Pathology (ISUP) Consensus Conference 
on Gleason Grading of Prostatic Carcinoma. Am. J. Surg. Pathol. 41 (4), e1–e7. https://doi.org/10.1097/PAS.0000000000000820. 
[58] Furlan, A., Borhani, A.A., Westphalen, A.C., 2018. Multiparametric MR imaging of the prostate: interpretation including prostate 












[59] Brown, L.C., Ahmed, H.U., Faria, R., El-Shater Bosaily, A., Gabe, R., Kaplan, R.S., et al., 2018. Multiparametric MRI to improve 
detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study. Health Technol. 
Assess. 22 (39), 1–176. https://doi.org/10.3310/hta22390. 
[60] Thai, J.N., Narayanan, H.A., George, A.K., Siddiqui, M.M., Shah, P., Mertan, F.V., et al., 2018. Validation of PI-RADS Version 2 in 
transition zone lesions for the detection of prostate cancer. Radiology 288 (2), 485–491. https://doi.org/10.1148/radiol.2018170425. 
[61] Padhani, A.R., Weinreb, J., Rosenkrantz, A.B., Villeirs, G., Turkbey, B., Barentsz, J., 2018. Prostate Imaging-Reporting and Data 
System Steering Committee: PI-RADS v2 status update and future directions. Eur. Urol. Jun 13. Pii, S0302-2838(18)30424-X. 
https://doi.org/10.1016/j.eururo.2018.05.035. 
[62] Polanec, S.H., Helbich, T.H, Bickel, H., Wengert, G.J., Pinker, K., Spick, C., 2018. Quantitative apparent diffusion coefficient 
derived from diffusion-weighted imaging has the potential to avoid unnecessary MRI-guided biopsies of mpMRI-detected PI-RADS 4 
and 5 lesions. Invest. Radiol. Jul 6. https://doi.org/10.1097/RLI.0000000000000498. 
[63] Osses, D.F., van Asten, J.J., Tijsterman, J.D., 2018. Cognitive-targeted versus magnetic resonance imaging-guided prostate 
biopsy in prostate cancer detection. Curr. Urol. 11 (4), 182–188. https://doi.org/10.1159/000447216. 
[64] Das, C.J., Razik, A., Sharma, S., 2018. Magnetic resonance imaging-transrectal ultrasound fusion biopsy of the prostate – an 
update. Semin. Roentgenol. 53 (3), 219–226. https://doi.org/10.1053/j.ro.2018.04.003. 
[65] Fendler, W.P., Eiber, M., Beheshti, M., Bomanji, J., Ceci, F., Cho, S., et al., 2017. 68Ga-PSMA PET/CT: Joint EANM and SNMMI 
procedure guideline for prostate cancer imaging: version 1.0. Eur. J. Nucl. Med. Mol. Imaging 44, 1014–1024. 
https://doi.org/10.1007/s00259-017-3670-z. 
[66] Poeppel, T.D., Handkiewicz-Junak, D., Andreeff, M., Becherer, A., Bockisch, A, Fricke, E., et al., 2018. EANM Guideline for 
radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 45, 824–845. 
[67] Delgado Bolton, R.C., Giammarile, F., 2018. Bone radionuclide therapy and increased survival with radium-223 is the way to go 
for nuclear medicine: the offer that oncologists cannot refuse. Eur. J. Nucl. Med. Mol. Imaging 45, 822–823. 
https://doi.org/10.1007/s00259-017-3913-z. 
[68] Virgolini, I., Decristoforo, C., Haug, A., Fanti, S., Uprimny, C., 2018. Current status of theranostics in prostate cancer. Eur. J. Nucl. 
Med. Mol. Imaging 45, 471–495. https://doi.org/10.1007/s00259-017-3882-2. 
[69] Carneiro, A., Sanchez-Salas, R., 2018. Re: Focal therapy in primary localised prostate cancer: the European Association of 
Urology position in 2018. Eur. Urol. 4 (2), 234. https://doi.org/10.1016/j.eururo.2018.03.023. 
[70] Brausi, M., 2017. Re: Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: early outcomes 
from a randomised controlled phase 3 study. Eur. Urol. 72 (5), 856–857. https://doi.org/10.1016/j.eururo.2017.07.029. 
[71] Barocas, D.A., Alvarez, J., Resnick, M.J., Koyama, T., Hoffman, K.E., Tyson, M.D., et al., 2017. Association between radiation 
therapy, surgery, or observation for localized prostate cancer and patient-reported outcomes after 3 years. JAMA 317 (11), 1126–
1140. https://doi.org/10.1001/jama.2017.1704. 
[72] Sini, C., Noris Chiorda, B., Gabriele, P., Sanguineti, G., Morlino, S., Badenchini F6, Patient-reported intestinal toxicity from whole 
pelvis intensity-modulated radiotherapy: first quantification of bowel dose-volume effects. Radiother. Oncol. 124 (2), 296–301. 
https://doi.org/10.1016/j.radonc.2017.07.005. 
[73] Royal College of Radiologists, 2012. The role and development of afterloading brachytherapy in the United Kingdom. BFCO(12)3. 
https://www.rcr.ac.uk/publication/role-and-development-afterloading-brachytherapy-services-united-kingdom. 
[74] Attard, G., Borre, M., Gurney, H., Loriot, Y., Andresen-Daniil, C., Kalleda, R., et al., 2018. Abiraterone alone or in combination with 
enzalutamide in metastatic castration-resistant prostate cancer with rising prostate-specific antigen during enzalutamide treatment. J. 
Clin. Oncol. 36 (25), 2639–2646. https://doi.org/10.1200/JCO.2018.77.9827. 
[75] Tannock, I.F., 2017. Abiraterone in metastatic prostate cancer. N. Engl. J.Med. 377 (17), 1695. 
https://doi.org/10.1056/NEJMc1711029. 
[76] Hussain, M., Fizazi, K., Saad, F., Rathenborg, P., Shore, N., Ferreira, U., 2018. Enzalutamide in men with nonmetastatic, 
castration-resistant prostate cancer. N. Engl. J. Med. 378 (26), 2465–2474. https://doi.org/10.1056/NEJMoa1800536.  
[77] James, N.D., de Bono, J.S., Spears, M.R., Clarke, N.W., Mason, M.D., Dearnaley, D.P., et al., 2017. Abiraterone for prostate 
cancer not previously treated with hormone therapy. N. Engl. J. Med. 377 (4), 338–351. https://doi.org/10.1056/NEJMoa1702900. 
[78] Vale, C.L., Fisher, D.J., White, I.R., Carpenter, J.R., Burdett, S., Clarke, N.W., et al., 2018. What is the optimal systemic treatment 
of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis. Ann. Oncol. 29 
(5), 1249–1257. https://doi.org/10.1093/annonc/mdy071. 
[79] Saad, F., Sternberg, C.N., Mulders, P.F.A., Niepel, D., Tombal, B.F., 2018. The role of bisphosphonates or denosumab in light of 
the availability of new therapies for prostate cancer. Cancer Treat. Rev. 68, 25–37. https://doi.org/10.1016/j.ctrv.2018.04.014. 
[80] Stacey, D., Taljaard, M., Breau, R.H., Baba, N., Blackmore, T., Boland, L., et al., 2018. A patient decision aid for men with 
localized prostate cancer: a comparative case study of natural implementation approaches. Cancer Nurs. Oct 12. 
https://doi.org/10.1097/NCC.0000000000000651. 
[81] Colasante, A., Augurio, A., Basilico, R., Cotroneo, A.R., Di Sciascio, M.B., Gaspari, G., et al., 2018. A multidisciplinary group for 
prostate cancer management: a single institution experience. Oncol. Lett. 15 (2), 1823–1828. https://doi.org/10.3892/ol.2017.7506. 
[82] Cockle-Hearne, J., Charnay-Sonnek, F., Denis, L., Fairbanks, H.E., Kelly, D., Kav, S., et al., 2013. The impact of supportive 
nursing care on the needs of men with prostate cancer: a study across seven European countries. Br. J. Cancer 109 (8), 2121–2130. 
https://doi.org/10.1038/bjc.2013.568. 
[83] Watson, E.K., Shinkins, B., Matheson, L., Burns, R.M., Frith, E., Neal, D., et al., 2018. Supporting prostate cancer survivors in 
primary care: Findings from a pilot trial of a nurse-led psycho-educational intervention (PROSPECTIV). Eur. J. Oncol. Nurs. 32, 73–
81. https://doi.org/10.1016/j.ejon.2017.12.002. 
[84] Johnson, H., 2016. Transferring hospital based prostate cancer care into community based nurse-led clinics. Quality in Care. 
http://bit.ly/2IyqKFM. 
[85] Droz, J.P., Boyle, H., Albrand, G., Mottet, N., Puts, M., 2017. Role of geriatric oncologists in optimizing care of urological oncology 
patients. Eur. Urol. Focus 3 (4-5), 385–394. https://doi.org/10.1016/j.euf.2017.10.012. 
[86] Monfardini, S., Morlino, S., Valdagni, R., Catanzaro, M., Tafa, A., Bortolato, B., et al., 2017. Follow-up of elderly patients with 
urogenital cancers: evaluation of geriatric care needs and related actions. J Geriatr. Oncol. 8 (4), 289–295. 
https://doi.org/10.1016/j.jgo.2017.02.011. 
[87] Droz, J.P., Albrand, G., Gillessen S., Hughes, S., Mottet, N., Oudard, S., 2017. Management of prostate cancer in elderly 
patients: recommendations of a task force of the International Society of Geriatric Oncology. Eur. Urol. 72 (4), 521–531. 
https://doi.org/10.1016/j.eururo.2016.12.025. 
[88] Petit-Monéger, A., Rainfray, M., Soubeyran, P., Bellera, C.A., Mathoulin-Pélissier, S., 2016. Detection of frailty in elderly cancer 
patients: improvement of the G8 screening test. J. Geriatr. Oncol. 7 (2), 99–107. https://doi.org/10.1016/j.jgo.2016.01.004. 
[89] Wildiers, H., Heeren, P., Puts, M., Topinkova, E., Janssen-Heijnen, M.L., Extermann, M., et al., 2014. International Society of 
Geriatric Oncology consensus on geriatric assessment in older patients with cancer. J. Clin. Oncol. 32 (24), 2595–2603, 
https://doi.org/10.1200/JCO.2013.54.8347. 
[90] Borson, S., Scanlan, J.M., Chen, P., Ganguli, M., 2003. The Mini-Cog as a screen for dementia: validation in a population-based 













[91] European Society of Oncology Pharmacy, 2014. Quality Standard for the Oncology Pharmacy Service (QuapoS 5). 
http://www.esop.li/activities.php. 
[92] Chambers, S.K., Zajdlewicz, L., Youlden, D.R., Holland, J.C., Dunn, J., 2014. The validity of the distress thermometer in prostate 
cancer populations. Psychooncology 23 (2), 195–203. https://doi.org/10.1002/pon.3391. 
[93] Parahoo, K., McDonough, S., McCaughan, E., Noyes, J., Semple, C., Halstead, E.J., et al., 2015. Psychosocial interventions for 
men with prostate cancer: a Cochrane systematic review. BJU Int. 116 (2), 174-183. https://doi.org/10.1111/bju.12989. 
[94] National Comprehensive Cancer Network, 2003. Distress management. Clinical practice guidelines. J. Natl. Compr. Canc. Netw. 
1 (3), 344–374. http://www.jnccn.org/content/1/3/344.long. 
[95] Hyde, M.K., Legg, M., Occhipinti, S., Lepore, S.J., Ugalde, A., Zajdlewicz, L., et al., 2018. Predictors of long-term distress in 
female partners of men diagnosed with prostate cancer. Psychooncology 27 (3), 946–954. https://doi.org/10.1002/pon.4617. 
[96] Whitney, H., Islam, T., 2015. Six month pilot analysis: improving rehabilitation for men with prostate cancer in North East London. 
Available at: https://prostatecanceruk.org/media/2492260/six-month-pilot-analysis-for-improving-rehabilitation-for-men-with-prostate-
cancer.pdf. 
[97] Bernardo-Filho, M., Barbosa Júnior, M.L., da Cunha Sá-Caputo, D., de Aguiar Ede, O., de Lima, R.P., Santos-Filho, S.D., et al., 
2014. The relevance of the procedures related to the physiotherapy in the interventions in patients with prostate cancer: short review 
with practice approach. Int. J. Biomed. Sci. 10 (2), 73–84. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4092084. 
[98] Haun, M.W., Estel, S., Rücker, G., Friederich, H.C., Villalobos, M., Thomas, M., et al., 2017. Early palliative care for adults with 
advanced cancer. Cochrane Database Syst. Rev. 12 6, CD011129. https://doi.org/10.1002/14651858.CD011129.pub2. 
[99] Kavalieratos, D., Corbelli, J., Zhang, D., Dionne-Odom, J.N., Ernecoff, N.C., Hanmer, J., et al., 2016. Association between 
palliative care and patient and caregiver outcomes: a systematic review and meta-analysis. JAMA 316 (20), 2104–2114. 
https://doi.org/10.1001/jama.2016.16840. 
[100] Sullivan, P.W., Mulani, P.M., Fishman, M., Sleep, D., 2007. Quality of life findings from a multicenter, multinational, observational 
study of patients with metastatic hormone-refractory prostate cancer. Qual. Life Res. 16 (4), 571–575. https://doi.org/10.1007/s11136-
006-9156-2. 
[101] Torvinen, S., Färkkilä, N., Sintonen, H., Saarto, T., Roine, R.P., Taari, K., 2013. Health-related quality of life in prostate cancer. 
Acta Oncol. 52 (6),1094–1101. https://doi.org/10.3109/0284186X.2012.760848. 
[102] Ferrell, B.R., Temel, J.S., Temin, S., Alesi, E.R., Balboni, T.A., Basch, E.M., et al., 2017. Integration of palliative care into 
standard oncology care: American Society of Clinical Oncology Clinical Practice Guideline Update. J. Clin. Oncol. 35 (1), 96–112. 
https://doi.org/10.1200/JCO.2016.70.1474. 
[103] Quill, T.E., Abernethy, A.P., 2013. Generalist plus specialist palliative care – creating a more sustainable model. N. Engl. J. Med. 
368 (13), 1173–1175. https://doi.org/10.1056/NEJMp1215620. 
[104] Hui, D., Mori, M., Watanabe, S.M., Caraceni, A., Strasser, F., Saarto, T., et al., 2016. Referral criteria for outpatient specialty 
palliative cancer care: an international consensus. Lancet Oncol. 17 (12), e552–e559. https://doi.org/10.1016/S1470-2045(16)30577-
0. 
[105] Ljunggren, C., Ströberg, P., 2015. Improvement in sexual function after robot-assisted radical prostatectomy: A rehabilitation 
program with involvement of a clinical sexologist. Cent. European J. Urol. 68 (2), 214–220. 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4526602. 
[106] Denis, L., 2011. Prostate cancer units (PCU): a patients’ perspective. Ecancermedicalscience 5, ed10. 
https://dx.doi.org/10.3332%2Fecancer.2011.ed10. 
[107] Wind, A., Rajan, A., van Harten, W.H., 2016. Quality assessments for cancer centers in the European Union. BMC Health Serv. 
Res. 16, 474, https://doi.org/10.1186/s12913-016-1738-2. 
[108] Benstead, K., Turhal, N.S., O’Higgins, N., Wyld, L., Czarnecka-Operacz, M., Gollnick, H., et al., 2017. Multidisciplinary training of 
cancer specialists in Europe. Eur. J. Cancer 83, 1–8. https://doi.org/10.1016/j.ejca.2017.05.043. 
[109] Van Hemelrijck, M., Wigertz, A., Sandin, F., Garmo, H., Hellström, K., Fransson, P., et al., 2013. Cohort profile: the National 
Prostate Cancer Register of Sweden and Prostate Cancer data Base Sweden 2.0. Int. J. Epidemiol. 42 (4), 956–967. 
https://doi.org/10.1093/ije/dys068. 
[110] Evans, S.M., Millar, J.L., Moore, C.M., Lewis, J.D., Huland, H., Sampurno, F., et al., 2017. Cohort profile: the TrueNTH Global 
Registry – an international registry to monitor and improve localised prostate cancer health outcomes. BMJ Open 7 (11), e017006. 
https://doi.org/10.1136/bmjopen-2017-017006. 
Jo
ur
na
l P
re
-p
ro
of
